DCGI Approves AstraZeneca’s Drug for Treatment of High-risk Early Breast Cancer
On Friday, the Drugs Controller General of India (DCGI) has given its market approval to the drug Lynparza (Olaparib) as a monotherapy for the adjuvant...
Tag : breast cancer
Mylan-Biocon’s breast cancer biosimilar receives ANVISA approval
Biocon and Mylan’s proposed trastuzumab has received approval from Brazilian regulatory agency ANVISA, through their partner Libbs Farmaceutica (Libbs). The approved product is co-developed by Biocon...
